2cureX AB Cash Flow Conversion Efficiency

Latest as of June 2025: 3.288x

2cureX AB cash flow conversion efficiency. Based on the latest financial reports, 2cureX AB (2CUREX) has a cash flow conversion efficiency ratio of 3.288x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.06 Million ≈ $221.47K USD) by net assets (Skr626.00K ≈ $67.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of 2cureX AB (2015–2024)

Cash flow conversion efficiency of 2cureX AB from 2015 to 2024. This chart illustrates how 2cureX AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 2CUREX stock price and chart for real-time trading data and today's change.

2cureX AB Cash Flow Conversion Ratio Explained

2cureX AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

2cureX AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 2cureX AB ranked by their cash flow conversion efficiency. Also see 2cureX AB (2CUREX) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
BEACN Wizardry & Magic Inc V:BECN	0.886x
Starbox Group Holdings Ltd. Ordinary Shares NASDAQ:STBX	-0.001x
Tracsis Plc LSE:TRCS	0.106x
Sky Gold Corp V:SKYG	-0.256x
Ambipar Emergency Response NYSE:AMBIQ	0.074x
Universal Ibogaine Inc V:IBO	-0.405x
Altiplano Metals Inc V:APN	3.221x
Baring Emerging Europe Plc LSE:BEMO	0.014x

Annual Cash Flow Conversion Efficiency for 2cureX AB (2015–2024)

The table below shows the annual cash flow conversion efficiency of 2cureX AB from 2015 to 2024. Review 2cureX AB (2CUREX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr5.10 Million ≈ $548.73K	Skr-4.63 Million ≈ $-497.83K	-0.907x	+64.90%
2023-12-31	Skr12.08 Million ≈ $1.30 Million	Skr-31.22 Million ≈ $-3.36 Million	-2.585x	-297.53%
2022-12-31	Skr43.03 Million ≈ $4.63 Million	Skr-27.98 Million ≈ $-3.01 Million	-0.650x	-162.37%
2021-12-31	Skr74.34 Million ≈ $8.00 Million	Skr-18.43 Million ≈ $-1.98 Million	-0.248x	-24.76%
2020-12-31	Skr58.86 Million ≈ $6.33 Million	Skr-11.69 Million ≈ $-1.26 Million	-0.199x	+29.07%
2019-12-31	Skr28.08 Million ≈ $3.02 Million	Skr-7.86 Million ≈ $-846.29K	-0.280x	-431.76%
2018-12-31	Skr13.62 Million ≈ $1.47 Million	Skr1.15 Million ≈ $123.76K	0.084x	+139.30%
2017-12-31	Skr20.24 Million ≈ $2.18 Million	Skr-4.35 Million ≈ $-467.91K	-0.215x	-240.95%
2016-12-31	Skr7.91 Million ≈ $851.78K	Skr1.21 Million ≈ $129.84K	0.152x	+160.87%
2015-12-31	Skr8.19 Million ≈ $881.25K	Skr-2.05 Million ≈ $-220.70K	-0.250x	--

About 2cureX AB

ST:2CUREX Sweden Biotechnology

Market Cap

$1.13 Million

Skr10.54 Million SEK

Market Cap Rank

#30583 Global

#699 in Sweden

Share Price

Skr0.42

Change (1 day)

-12.13%

52-Week Range

Skr0.42 - Skr2.65

All Time High

Skr28.20